Chung Y S, Nakata B, Tanaka H, Kubo T, Satake K, Sowa M, Umeyama K
First Department of Surgery, Osaka City University Medical School, Japan.
Nihon Geka Gakkai Zasshi. 1990 Feb;91(2):228-33.
Basic evaluation of SPan-1 assay (SPan-1 RIA. BEAD) and clinical significance of serum SPan-1 levels for the diagnosis of pancreatic cancer were studied. This assay was reproducible, reliable and simple to perform. It required minimal samples (duplicate 50 microliters) and may be done within 4 hrs. Normal subjects (N = 1182) had serum SPan-1 antigen levels which ranged 0 to 42.8 units/ml with a mean of 7.5 units/ml and above 40 units/ml was considered to be positive. SPan-1 antigen levels in cultured medium of four out of five pancreatic cancer cell lines showed more than 1000 units/ml by this assay. While over 90% of pancreatic cancer patients had elevated levels of serum SPan-1 antigen, only 0-17% of patients with other malignant and non malignant gastrointestinal diseases such as pancreatitis (chronic or acute), gastric cancer or colon cancer had above normal levels. Furthermore, levels of serum SPan-1 antigen correlated well with treatment and recurrence of disease in patients with pancreatic and gastric cancer. These results suggest that determination of serum SPan-1 antigen levels by this assay kit is useful for the diagnosis and monitoring of pancreatic cancer.
研究了SPan-1检测法（SPan-1放射免疫分析. 微珠法）的基本评估以及血清SPan-1水平在胰腺癌诊断中的临床意义。该检测法具有可重复性、可靠性且操作简单。它所需样本量极少（50微升重复样本），且可在4小时内完成。1182名正常受试者的血清SPan-1抗原水平在0至42.8单位/毫升之间，平均为7.5单位/毫升，40单位/毫升以上被视为阳性。通过该检测法，五种胰腺癌细胞系中有四种的培养基中的SPan-1抗原水平显示超过1000单位/毫升。虽然超过90%的胰腺癌患者血清SPan-1抗原水平升高，但在其他恶性和非恶性胃肠道疾病（如胰腺炎（慢性或急性）、胃癌或结肠癌）患者中，只有0 - 17%的患者水平高于正常。此外，血清SPan-1抗原水平与胰腺癌和胃癌患者的疾病治疗及复发情况密切相关。这些结果表明，使用该检测试剂盒测定血清SPan-1抗原水平对胰腺癌的诊断和监测有用。
